MTOR and prostate carcinoma: This is not exceptional, and except for some combined therapies that include PI3K, Akt, mTOR inhibitors, e.g., for breast and prostate cancer subtypes [36, 37, 42], treatment of solid tumors with these inhibitors has been often ineffective [12, 16, 17, 42, 43].